News for Paragon Care Limited (PGC.AX)

Published at

Mar 29, 2024 8:10 PM

by gurufocus.com

positive

positive

Half Year 2023 Paragon Care Ltd Earnings Call Transcript

Feb 21, 2023 / 11:00PM GMTOperator Good day and thank you for standing by. Welcome to the Paragon Care first half '23 results call. (Operator Instructions) I wo

PGC.AX

Read more →
Published at

May 10, 2023 5:57 PM

by stockhead.com.au

mixed

mixed

Check Up Budget Edition: Which ASX healthcare stocks will reap benefits from the Budget?

Telehealth, mental health and aged care stocks rallied on Wednesday following the Budget announcement which include billions for healthcare.

REG.AX ONE.AX LME.AX JHC.AX GLH.AX 1ST.AX RGS.AX PXSLY PXS.AX PBP.AX OCC.AX MEB.AX MDBIF IVX.AX IPDQF IPD.AX IMM.AX HSC.AX CGS.AX ATX.AX ARUXF ADR.AX ACR.AX VTG.AX VLS.AX SOMNF SOM.AX SCU.AX RNO.AX RHT.AX PGC.AX PCK.AX EYE.AX CMP.AX CAN.AX CAJ.AX BXN.AX AMT.AX

Read more →
Published at

May 4, 2023 6:40 PM

by stockhead.com.au

mixed

mixed

Trading Places: Beer giant Kirin wants to cure your hangover too, snapping up Blackmores for $1.2bn

Japanese beer comany Kirin has become a substantial shareholder in Blackmores (ASX:BKL) with an 18% stake following $1.2 billion takeover bid.

ZYA.DE STT.MX STT SFR.AX S1TT34.SA PBH.AX GOR.AX BKL.AX ASX.AX 0L9G.L PGC.AX NCB.DE MLX.AX LIC.AX JPMML JPMCL.SN JPMC.BA JPM JBH.AX FARYF FAR.AX BACCL.SN BAC.SN BAC.MX BAC MVF.AX MSCL.SN IFT.AX EBG.AX

Read more →
Published at

Apr 30, 2023 7:20 PM

by stockhead.com.au

mixed

mixed

Check Up: Healthcare is ripe for AI disruption, and Telix Pharma’s first $100m+ quarterly sales

The healthcare sector is ripe for disruption and artificial intelligence will play a big part in future drug discovery.

PSQ.AX PGC.AX OSX.AX OPT.AX OPT NOXOF NOX.AX IUGNF IMU.AX GSS.AX CYP.AX CKDXF BPH.AX ATX.AX 4DX.AX ZNO.AX SCU.AX RSH.AX PXSLY PXS.AX PAB.AX OCC.AX NC6.AX KZA.AX KMLXF IHL.AX IDT.AX FDMDF DVL.AX CMP.AX BITRF BIT.AX ARUXF AMT.AX ACR.AX 1AD.AX ZLD.AX VTG.AX VLS.AX UBI.AX TD1.AX SOMNF SOM.AX RNO.AX RHY.AX RHT.AX RGS.AX RAC.AX PYC.AX PNV.AX PCK.AX PBP.AX OVN.AX OSL.AX ONE.AX OIL.AX NYR.AX NXSCF NXS.AX MXC.AX MX1.AX MVF.AX MEM.AX MEB.AX MDR.AX MDC.AX MDBIF LBT.AX IVX.AX IPDQF IPD.AX IMRNW IMRN IMM.AX IMC.AX ICR.AX HCT.AX GTG.AX GLH.AX EYE.AX DXB.AX CSL.AX CPH.AX CGS.AX CAN.AX CALZF CAJ.AX BXN.AX BWXXF BWX.AX BNOEF BNO.AX AT1.AX ARX.AX AMDHF ALC.AX ADR.AX ADO.AX 1ST.AX

Read more →
Published at

Apr 26, 2023 6:40 PM

by stockhead.com.au

positive

positive

MoneyTalks: Brokers see blue sky for these 3 ASX biotech stocks, with massive price targets

Brokers Euroz Hartleys and Taylor Collison have put lofty target prices on 3 ASX biotechs - Pharmaxis, Botanix and Paragon Care.

PXS.AX PGC.AX EZL.AX

Read more →
Published at

Mar 5, 2023 7:20 PM

by stockhead.com.au

mixed

mixed

Check Up: Almost half a billion US dollars raised to bring back mammoth, dodo, and Tassie tiger

Colossal Biosciences’ plans to bring the Tasmanian tiger and woolly mammoth back to life, but now it’s also betting on the iconic dodo.

TD1.AX RGS.AX RAC.AX FFC.AX EZL.AX PYC.AX PAB.AX OPT.AX OPT MX1.AX CMP.AX CKDXF AMT.AX VTG.AX VLS.AX SOMNF SOM.AX SCU.AX RNO.AX RHT.AX PXSLY PXS.AX PSQ.AX PNV.AX PGC.AX PBP.AX ONE.AX OCC.AX NYR.AX NC6.AX MVF.AX MEM.AX MEB.AX MDBIF LBT.AX IVX.AX IPDQF IPD.AX IMM.AX HCT.AX GTG.AX GSS.AX EYE.AX CGS.AX CAN.AX CALZF CAJ.AX BXN.AX BWXXF BWX.AX BNOEF BNO.AX ATX.AX ARUXF AMDHF ADR.AX ACR.AX

Read more →
Published at

Feb 1, 2023 5:46 PM

by stockhead.com.au

mixed

mixed

Check Up: The FDA refuses to give CBD a green light, but market doesn’t seem to care

The FDA declined regulate CBD-based supplements and food citing safety reasons, but the CBD index keeps going up.

PYC.AX PSQ.AX PGC.AX MSB.AX KZA.AX EYE.AX DVL.AX CAN.AX BXN.AX BNOEF BNO.AX ADO.AX SOMNF SOM.AX RSH.AX RHT.AX RGS.AX OSX.AX OSL.AX ONE.AX OIL.AX NXSCF NXS.AX MEB.AX MDC.AX MDBIF KMLXF IVX.AX IUGNF IMU.AX IDT.AX GLH.AX CYP.AX CMP.AX CAJ.AX AT1.AX ADR.AX 1ST.AX ZNO.AX ZLD.AX VTG.AX VLS.AX UBI.AX TD1.AX SCU.AX RNO.AX RHY.AX RAC.AX PXSLY PXS.AX PNV.AX PCK.AX PBP.AX PAB.AX OVN.AX OPT.AX OPT OCC.AX NYR.AX NOXOF NOX.AX NC6.AX MXC.AX MX1.AX MVF.AX MEM.AX MDR.AX LBT.AX IPDQF IPD.AX IMRNW IMRN IMM.AX IMC.AX IHL.AX ICR.AX HCT.AX GTG.AX GSS.AX FDMDF DXB.AX CPH.AX CKDXF CGS.AX CALZF BWXXF BWX.AX BPH.AX BITRF BIT.AX ATX.AX ARX.AX ARUXF AMT.AX AMDHF ALC.AX ACR.AX 4DX.AX 1AD.AX

Read more →
Published at

Jan 19, 2023 5:50 PM

by stockhead.com.au

mixed

mixed

Check Up: Japan’s startup OUI wants to halve the world’s blindness with its smartphone device

Japanese startup OUI Inc says it is on a mission to halve the world's blindness with its smartphone-based device.

ZNO.AX ZLD.AX RAP.AX PSQ.AX PIQ.AX PBP.AX PAA.AX MXC.AX IPDQF IPD.AX IDT.AX GLH.AX CGS.AX BXN.AX 1AD.AX SOMNF SOM.AX SHL.AX RSH.AX RGS.AX PGC.AX PCK.AX OVN.AX OSX.AX OSL.AX OIL.AX NYR.AX NXSCF NXS.AX MX1.AX MDC.AX LBT.AX KZIA KZA.AX KMLXF IVX.AX IMMP IMM.AX IHL.AX GSS.AX FDMDF DVL.AX CYP.AX CPH.AX CAN.AX BWXXF BWX.AX BPH.AX BNOEF BNO.AX BITRF BIT.AX AT1.AX ARX.AX AKU.TO AKU ADR.AX 4DX.AX 1ST.AX VTG.AX VLS.AX UBI.AX SCU.AX RNO.AX RHY.AX RHT.AX RAC.AX PYC.AX PXSLY PXS.AX PNV.AX PAB.AX OPT.AX OPT ONE.AX OCC.AX NOXOF NOX.AX NC6.AX MVF.AX MEM.AX MEB.AX MDR.AX MDBIF IUGNF IMU.AX IMRNW IMRN IMC.AX ICR.AX HCT.AX EYE.AX DXB.AX CMP.AX CKDXF CALZF CAJ.AX ATX.AX ARUXF AMT.AX AMDHF ALC.AX ADO.AX ACR.AX

Read more →
Published at

Jan 4, 2023 6:02 PM

by stockhead.com.au

mixed

mixed

Check Up: Moderna posts crazy cancer vaccine results, says melanoma recurrence down by almost half

Moderna’s stock price rose in late December after the company revealed that a vaccine for melanoma showed encouraging results.

TD1.AX RSH.AX PCK.AX MX1.AX KMLXF DVL.AX CAJ.AX BNOEF BNO.AX ARX.AX ADR.AX 1ST.AX ZNO.AX RHY.AX RAC.AX PYC.AX PSQ.AX PGC.AX OVN.AX OSX.AX ONE.AX OCC.AX NOXOF NOX.AX NC6.AX MDC.AX KZA.AX IPDQF IPD.AX IDT.AX GTG.AX CYP.AX CPH.AX CAN.AX BXN.AX BWXXF BWX.AX BPH.AX BITRF BIT.AX ATX.AX ZLD.AX VTG.AX VLS.AX UBI.AX SOMNF SOM.AX SCU.AX RNO.AX RHT.AX RGS.AX PXSLY PXS.AX PNV.AX PBP.AX PAB.AX OSL.AX OPT.AX OPT OIL.AX NYR.AX NXSCF NXS.AX MXC.AX MVF.AX MEM.AX MDR.AX LBT.AX IVX.AX IUGNF IMU.AX IMRNW IMRN IMM.AX IMC.AX IHL.AX ICR.AX HCT.AX GSS.AX GLH.AX FDMDF EYE.AX DXB.AX CMP.AX CKDXF CGS.AX CALZF AT1.AX ARUXF AMT.AX AMDHF ALC.AX ADO.AX ACR.AX 4DX.AX 1AD.AX

Read more →
Published at

Dec 30, 2022 6:47 AM

by stockhead.com.au

mixed

mixed

Weekly Small Cap Wrap: ASX small caps manage a gain as we limp towards the New Year

The Emerging Companies index managed to lift slightly this week to 0.61% but all sectors finished in the red.

SYR.AX SOR.AX RDBBY RDBBF RBL.AX QHL.AX OBM.AX MME.AX LIFX INR.AX GSCCF FDMDF ENR.AX CE1.AX BRK.AX BCK.AX ATS.AX 4DX.AX 360.AX VTMXF VML.AX TMH.AX SVM.AX RFG.AX PYC.AX OPY.AX NTD.AX NET.AX MLXEF MLX.AX LCL.AX HLA.AX GNX.AX FTZ.AX EYE.AX EVS.AX ELTLF ELT.AX E25.AX CGF.AX AVR.AX AMI.AX WSP.AX WKT.AX WHSPF TTM.AX TIP.AX SVY.AX SDV.AX PGC.AX ORR.AX NVX.AX NVNXF NGY.AX MTC.AX MRL.AX MFB.AX MCM.AX LME.AX KLL.AX KKO.AX FML.AX EOFBF EOF.AX EGR.AX DTZ.AX DGL.AX DGC.NZ CYM.AX CLU.AX CAF.AX BOC.AX BNL.AX BBX.AX ASP.AX ARL.AX AHQDB.AX AHQ.AX

Read more →
Published at

Nov 30, 2022 8:10 PM

by stockhead.com.au

mixed

mixed

Check Up: The world's most expensive drug costs $3.5 MILLION a shot

The US FDA has just approved the world’s most expensive drug. CSL Behring’s hemophilia B gene therapy costs US$3.5m a dose.

PAB.AX OCC.AX NC6.AX MDR.AX IMM.AX GTG.AX GSS.AX EYE.AX CSLN.MX CSLLY CSL.AX CMXHF BPH.AX SHL.AX RAC.AX PSQ.AX ONE.AX NYR.AX NXSCF NXS.AX MXC.AX KZA.AX FDMDF DXB.AX DVL.AX CYP.AX CPH.AX CGS.AX AT1.AX ARX.AX ARUXF AMDHF ALC.AX ACR.AX 4DX.AX ZNO.AX ZLD.AX VTG.AX VLS.AX UBI.AX TD1.AX SOMNF SOM.AX SCU.AX RSH.AX RNO.AX RHY.AX RHT.AX RGS.AX PYC.AX PXSLY PXS.AX PNV.AX PGC.AX PCK.AX PBP.AX OVN.AX OSX.AX OSL.AX OPT.AX OPT OIL.AX NOXOF NOX.AX MX1.AX MVF.AX MEM.AX MEB.AX MDC.AX MDBIF LBT.AX KMLXF IVX.AX IUGNF IPDQF IPD.AX IMU.AX IMRNW IMRN IMC.AX IHL.AX IDT.AX ICR.AX HCT.AX GLH.AX CMP.AX CKDXF CAN.AX CALZF CAJ.AX BXN.AX BWXXF BWX.AX BNOEF BNO.AX BITRF BIT.AX ATX.AX AMT.AX ADR.AX ADO.AX 1ST.AX 1AD.AX

Read more →
Published at

Nov 23, 2022 7:50 PM

by stockhead.com.au

mixed

mixed

How out of favour Biotech has a PR problem and could learn from Dr Karl

ASX health stocks have fallen out of favour in 2022 with a a rotation out of growth into value sectors but could it also do with better PR?

VTG.AX NEU.AX MXC.AX KZA.AX CSL.AX COH.AX BWXXF BWX.AX AT1.AX ADR.AX ADO.AX ZNO.AX ZLD.AX UBI.AX TD1.AX SHL.AX RSH.AX RHT.AX RAC.AX PNV.AX PBP.AX OVN.AX OSX.AX OSL.AX OCC.AX NOXOF NOX.AX MVF.AX MEM.AX MEB.AX MDC.AX MDBIF LBT.AX KMLXF IUGNF IMU.AX ICS.AX ICR.AX EYE.AX CPH.AX CMP.AX CALZF BXN.AX AMDHF 1ST.AX VLS.AX SOMNF SOM.AX SCU.AX RNO.AX RHY.AX RGS.AX PYC.AX PXSLY PXS.AX PSQ.AX PGC.AX PCK.AX PAB.AX OPT.AX OPT ONE.AX OIL.AX NYR.AX NXSCF NXS.AX MX1.AX MDR.AX IVX.AX IPDQF IPD.AX IMRNW IMRN IMM.AX IMC.AX IHL.AX IDT.AX HCT.AX GTG.AX GSS.AX GLH.AX FDMDF DXB.AX DVL.AX CYP.AX CKDXF CGS.AX CAN.AX CAJ.AX BPH.AX BNOEF BNO.AX BITRF BIT.AX ATX.AX ARX.AX ARUXF AMT.AX ALC.AX ACR.AX 4DX.AX 1AD.AX

Read more →
Published at

Nov 2, 2022 8:30 PM

by stockhead.com.au

mixed

mixed

Check Up: These 4 ASX healthcare stocks come with Strong Buy recommendations

Four ASX healthcare stocks have been rated as a ‘Strong Buy' by Morningstar’s consensus of brokers, making them hot tips.

ZNO.AX RHT.AX LBT.AX KZA.AX IUGNF IMU.AX ICR.AX EPN.AX ARX.AX ARUXF AMT.AX ALC.AX ACR.AX 1ST.AX ZLD.AX RAC.AX PNV.AX PBP.AX ONE.AX OIL.AX NXSCF NXS.AX MDR.AX IPDQF IPD.AX IMRNW IMRN IMC.AX GTG.AX GSS.AX GLH.AX FDMDF EYE.AX CYP.AX CALZF BNOEF BNO.AX 4DX.AX VTG.AX VLS.AX UBI.AX TD1.AX SOMNF SOM.AX SCU.AX RSH.AX RNO.AX RHY.AX RGS.AX PYC.AX PXSLY PXS.AX PSQ.AX PGC.AX PCK.AX PAB.AX OVN.AX OSX.AX OSL.AX OPT.AX OPT OCC.AX NYR.AX NOXOF NOX.AX NC6.AX MXC.AX MX1.AX MVF.AX MEM.AX MEB.AX MDC.AX MDBIF KMLXF IVX.AX IMM.AX IHL.AX IDT.AX HCT.AX DXB.AX DVL.AX CPH.AX CMP.AX CKDXF CGS.AX CAN.AX CAJ.AX BXN.AX BWXXF BWX.AX BPH.AX BITRF BIT.AX ATX.AX AT1.AX AMDHF ADR.AX ADO.AX 1AD.AX

Read more →
Published at

Oct 20, 2022 9:00 PM

by stockhead.com.au

mixed

mixed

Check Up: Only two healthcare IPOs from 2021 are gaining ground, could the rest be buying opportunities?

There were 191 ASX IPOs in calendar year 2021, and 15 of them were biotech stocks.But in 2022 there were only 3 biotech listings.

PXSLY PXS.AX PAB.AX OSL.AX MEM.AX ILA.AX GLH.AX CAJ.AX BPH.AX AMDHF AGN.AX ZLD.AX UBI.AX TD1.AX SCU.AX RSH.AX RNO.AX RHY.AX RGS.AX PYC.AX PGC.AX PBP.AX OSX.AX OPT.AX OPT OIL.AX OCC.AX NXSCF NXS.AX NOXOF NOX.AX NC6.AX MXC.AX MEB.AX MDR.AX MDC.AX MDBIF KMLXF IPDQF IPD.AX IMRNW IMRN IMC.AX IHL.AX HXL.AX GTG.AX EYE.AX DVL.AX CPH.AX CKDXF BWXXF BWX.AX BITRF BIT.AX AT1.AX ARUXF ACR.AX 1ST.AX ZNO.AX VTG.AX VLS.AX SOMNF SOM.AX RHT.AX RAC.AX PSQ.AX PNV.AX PCK.AX OVN.AX ONE.AX NYR.AX MX1.AX MVF.AX LBT.AX KZA.AX IVX.AX IUGNF IMU.AX IMM.AX IDT.AX ICR.AX HCT.AX GSS.AX FDMDF DXB.AX CYP.AX CMP.AX CGS.AX CAN.AX CALZF BXN.AX BNOEF BNO.AX ATX.AX ARX.AX AMT.AX ALC.AX ADR.AX ADO.AX ACW.AX 4DX.AX 1AD.AX

Read more →
Published at

Sep 7, 2022 10:10 PM

by stockhead.com.au

mixed

mixed

Check Up: As the pandemic winds down, what’s happening with Covid focused biotechs?

Winter’s nearly over and the Covid surge in Australia has slowed down dramatically. New cases are now rapidly declining.

ZNO.AX RNO.AX RGS.AX PNV.AX LCT.AX IUGNF IMU.AX IMM.AX GSS.AX CALZF BWXXF BWX.AX ANP.AX TD1.AX RSH.AX PXSLY PXS.AX OVN.AX OSX.AX OPT.AX OPT ONE.AX OIL.AX OCC.AX NOXOF NOX.AX KMLXF IPDQF IPD.AX IDT.AX ICR.AX GTG.AX GLH.AX FFC.AX EYE.AX DXB.AX CMP.AX CKDXF CASBF CAN.AX CAJ.AX BXN.AX BNOEF BNO.AX AMDHF ADR.AX 688185.SS 6185.HK ZLD.AX VTG.AX VLS.AX UBI.AX SOMNF SOM.AX SCU.AX RHY.AX RHT.AX RAP.AX RAC.AX PYC.AX PSQ.AX PGC.AX PCK.AX PBP.AX PAB.AX OSL.AX NYR.AX NXSCF NXS.AX NC6.AX MXC.AX MX1.AX MVF.AX MEM.AX MEB.AX MDR.AX MDC.AX MDBIF LBT.AX KZA.AX IVX.AX IMRNW IMRN IMC.AX IHL.AX HCT.AX FDMDF DVL.AX CYP.AX CPH.AX CGS.AX BITRF BIT.AX ATX.AX AT1.AX ARX.AX ARUXF AMT.AX ALC.AX ADO.AX ACR.AX 4DX.AX 1ST.AX 1AD.AX

Read more →
Published at

Jul 20, 2022 9:50 PM

by stockhead.com.au

mixed

mixed

Check Up: US FDA approves first clinical trial of naturally derived psychedelic drugs

In a ground-breaking development, the US FDA has just approved a clinical trial studying the effects of naturally derived psychedelic drugs.

ZNO.AX TD1.AX RNO.AX PYC.AX NXSCF NXS.AX MDC.AX IPDQF IPD.AX GSS.AX FH.NE FDMDF CAN.AX CAJ.AX BXN.AX BITRF BIT.AX ADR.AX 4DX.AX 1ST.AX VLS.AX RGS.AX RAP.AX RAC.AX PSQ.AX PCK.AX PBP.AX PAL.AX OSL.AX ONE.AX OCC.AX NC6.AX MXC.AX MX1.AX MDR.AX LGP.AX KZA.AX IVX.AX IMRNW IMRN IMC.AX EMD.AX BWXXF BWX.AX ATX.AX AMT.AX AMDHF 1AD.AX ZLD.AX VTG.AX UBI.AX SOMNF SOM.AX SCU.AX RSH.AX RHY.AX RHT.AX PXSLY PXS.AX PNV.AX PGC.AX PAB.AX OVN.AX OSX.AX OPT.AX OPT OIL.AX NYR.AX NOXOF NOX.AX MVF.AX MEM.AX MEB.AX MDBIF LBT.AX KMLXF IUGNF IMU.AX IMM.AX IHL.AX IDT.AX ICR.AX HCT.AX GTG.AX GLH.AX FFC.AX EYE.AX DXB.AX DVL.AX CYP.AX CPH.AX CMP.AX CKDXF CGS.AX CALZF BPH.AX BNOEF BNO.AX AT1.AX ARX.AX ARUXF ALC.AX ADO.AX ACR.AX

Read more →
Published at

Jul 6, 2022 9:50 PM

by stockhead.com.au

mixed

mixed

Check Up: These biotech themes got billions in VC funding. These ASX stocks could benefit

McKinsey showed that VCs ploughed US$35 billion into biotechs doing certain programs. Which ASX biotechs are doing similar programs?

TD1.AX PYC.AX PTX.AX PCK.AX OSX.AX OPL.AX IMM.AX FDMDF CYC.AX CHM.AX ADO.AX 4DX.AX ZLD.AX VLS.AX SUD.AX SOMNF SOM.AX RSH.AX RNO.AX RHY.AX RHT.AX RGS.AX RAP.AX PNV.AX PGC.AX PAB.AX ONE.AX OIL.AX NXSCF NXS.AX NOXOF NOX.AX NC6.AX MXC.AX MVF.AX MEM.AX MEB.AX MDC.AX MDBIF LBT.AX KZA.AX KMLXF IVX.AX IUGNF IMU.AX IHL.AX IDT.AX GTG.AX GSS.AX GLH.AX DXB.AX DVL.AX CYP.AX CPH.AX CAN.AX CALZF CAJ.AX AVR.AX AVH.AX ATX.AX AT1.AX ARX.AX ARUXF ADR.AX ACR.AX 1AD.AX ZNO.AX VTG.AX UBI.AX SCU.AX RAC.AX PXSLY PXS.AX PSQ.AX PBP.AX PAL.AX OVN.AX OSL.AX OPT.AX OPT OCC.AX NYR.AX MX1.AX MDR.AX IPDQF IPD.AX IMRNW IMRN IMC.AX ICR.AX HIQ.AX HCT.AX FFC.AX EYE.AX CMP.AX CKDXF CGS.AX BXN.AX BWXXF BWX.AX BPH.AX BNOEF BNO.AX BITRF BIT.AX AMT.AX AMDHF ALC.AX 1ST.AX

Read more →
Published at

Jun 22, 2022 10:00 PM

by stockhead.com.au

mixed

mixed

Check Up: Samsung and Big Pharma give big thumbs up to biotech sector

In a sign that the biotech industry could be making a big rebound, giant Samsung has just announced a US$360bn investment into biotechs.

ZLD.AX UBI.AX RGS.AX PNV.AX PAL.AX KZA.AX HCT.AX GTG.AX EYE.AX CMP.AX CGS.AX CALZF BNOEF BNO.AX ARUXF ACR.AX ZNO.AX TD1.AX RSH.AX RHY.AX PXSLY PXS.AX OSX.AX OSL.AX OCC.AX NYR.AX NXSCF NXS.AX NOXOF NOX.AX MXC.AX LBT.AX KMLXF IUGNF IPDQF IPD.AX IMU.AX IMRNW IMRN IMM.AX IMC.AX IHL.AX IDT.AX ICR.AX GSS.AX GLH.AX FDMDF DVL.AX CPH.AX CAN.AX CAJ.AX BXN.AX BPH.AX BITRF BIT.AX ADR.AX ADO.AX 4DX.AX 1ST.AX VTG.AX VLS.AX SOMNF SOM.AX SCU.AX RNO.AX RHT.AX RAP.AX RAC.AX PYC.AX PSQ.AX PIQ.AX PGC.AX PCK.AX PBP.AX PAB.AX OVN.AX OPT.AX OPT ONE.AX OIL.AX NC6.AX MX1.AX MVF.AX MEM.AX MEB.AX MDR.AX MDC.AX MDBIF IVX.AX HLS.AX FFC.AX DXB.AX CYP.AX CKDXF BWXXF BWX.AX ATX.AX AT1.AX ARX.AX AMT.AX AMDHF ALC.AX 1AD.AX

Read more →
Published at

Jun 8, 2022 9:21 PM

by stockhead.com.au

mixed

mixed

Check Up: Biotechs are getting crushed, but expert says we shouldn’t dismiss them

Biotech stocks are in a long form slump. Expert believes the sector is over saturated. But another says we should not rule them out.

RAC.AX PTX.AX PNV.AX PGC.AX NXSCF NXS.AX NC6.AX MDC.AX ICR.AX FFC.AX DXB.AX CYP.AX CPH.AX CALZF ARX.AX RHY.AX RAP.AX PYC.AX PSQ.AX PCK.AX PAB.AX OSX.AX ONE.AX OCC.AX NOXOF NOX.AX IUGNF IMU.AX BWXXF BWX.AX AMT.AX ADO.AX 1ST.AX ZNO.AX ZLD.AX VTG.AX VLS.AX UBI.AX TD1.AX SOMNF SOM.AX SCU.AX RSH.AX RNO.AX RHT.AX RGS.AX PXSLY PXS.AX PBP.AX PAL.AX OVN.AX OSL.AX OPT.AX OPT OIL.AX NYR.AX MXC.AX MX1.AX MVF.AX MEM.AX MEB.AX MDR.AX MDBIF LBT.AX KZA.AX KMLXF IVX.AX IPDQF IPD.AX IMRNW IMRN IMM.AX IMC.AX IHL.AX IDT.AX HCT.AX GTG.AX GSS.AX GLH.AX FDMDF EYE.AX DVL.AX CMP.AX CKDXF CGS.AX CAN.AX CAJ.AX BXN.AX BPH.AX BNOEF BNO.AX BITRF BIT.AX ATX.AX AT1.AX ARUXF AMDHF ALC.AX ADR.AX ACR.AX 4DX.AX 1AD.AX

Read more →
Published at

May 25, 2022 9:35 PM

by stockhead.com.au

mixed

mixed

Check Up: Here’s what’s in store for the Healthcare sector as the new government steps in

Labor has promised an additional $2.5 billion in aged care funding, additional to the $18.8 billion, five-year reform program.

SOMNF SOM.AX PXSLY PXS.AX OIL.AX NYR.AX IVX.AX IHL.AX FFC.AX CMP.AX BPH.AX AT1.AX ALC.AX 1ST.AX 1AD.AX ZLD.AX TD1.AX SCU.AX RNO.AX RHY.AX RHT.AX PYC.AX PCK.AX OSX.AX OCC.AX NXSCF NXS.AX NOXOF NOX.AX MXC.AX MX1.AX MDR.AX LBT.AX IPDQF IPD.AX GTG.AX GSS.AX GLH.AX FDMDF EYE.AX BNOEF BNO.AX BITRF BIT.AX ATX.AX ARUXF AMT.AX ADO.AX ACR.AX 4DX.AX ZNO.AX VTG.AX VLS.AX UBI.AX RSH.AX RGS.AX RAP.AX RAC.AX PSQ.AX PNV.AX PGC.AX PBP.AX PAL.AX PAB.AX OVN.AX OSL.AX OPT.AX OPT ONE.AX NC6.AX MVF.AX MEM.AX MEB.AX MDC.AX MDBIF KZA.AX KMLXF IUGNF IMU.AX IMRNW IMRN IMM.AX IMC.AX IDT.AX ICR.AX HCT.AX DXB.AX DVL.AX CYP.AX CPH.AX CKDXF CGS.AX CAN.AX CALZF CAJ.AX BXN.AX BWXXF BWX.AX ARX.AX AMDHF ADR.AX

Read more →